capecitabine-irinotecan — Competitive Intelligence Brief

capecitabine-irinotecan (capecitabine-irinotecan) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topoisomerase I inhibitor and thymidylate synthase inhibitor. Area: Oncology.

phase 3 Topoisomerase I inhibitor and thymidylate synthase inhibitor Topoisomerase I and thymidylate synthase Oncology Small molecule

Target snapshot

capecitabine-irinotecan (capecitabine-irinotecan) — Dutch Colorectal Cancer Group. Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
capecitabine-irinotecan TARGET	capecitabine-irinotecan	Dutch Colorectal Cancer Group	phase 3	Topoisomerase I inhibitor and thymidylate synthase inhibitor	Topoisomerase I and thymidylate synthase
aflibercept + FOLFIRI	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
FOLFIRI + bevacizumab	FOLFIRI + bevacizumab	Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)	phase 3	Chemotherapy + monoclonal antibody (anti-VEGF)	VEGF (bevacizumab component); topoisomerase I and thymidylate synthase (FOLFIRI components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topoisomerase I inhibitor and thymidylate synthase inhibitor class)

1. Dutch Colorectal Cancer Group · 1 drug in this class